LUPIN LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,580 INR | -1.47% |
|
-1.95% | +19.43% |
| Apr. 22 | INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains | RE |
| Apr. 22 | Lupin Launches Mirabegron Extended-Release Tablets in US | MT |
Business Summary
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Number of employees: 20,933
Sales per Business
| INR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 164,055 | 100.0 % | 166,417 | 100.0 % | +1.44% |
Sales per region
| INR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
India
40.0
%
| 64,596 | 39.4 % | 66,507 | 40.0 % | +2.96% |
United States
31.0
%
| 56,352 | 34.3 % | 51,584 | 31.0 % | -8.46% |
Others
29.0
%
| 43,107 | 26.3 % | 48,326 | 29.0 % | +12.11% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 96-12-31 | |
Johnny Mikell
PSD | President | - | - |
| Director of Finance/CFO | 59 | 07-08-12 | |
Shahin Fesharaki
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | - | |
| Director/Board Member | 50 | 95-12-31 | |
Ravik Agarwal
IRC | Investor Relations Contact | - | - |
Jon Stelzmiller
PRN | Corporate Officer/Principal | - | - |
Rajeev Sibal
PRN | Corporate Officer/Principal | - | - |
Yashwant Mahadik
HRO | Human Resources Officer | - | 18-07-09 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 15-10-26 | |
Mark McDade
BRD | Director/Board Member | 69 | 21-01-27 |
| Director/Board Member | 50 | 95-12-31 | |
| Chairman | 80 | 83-02-28 | |
| Director of Finance/CFO | 59 | 07-08-12 | |
| Chief Executive Officer | 56 | 96-12-31 | |
| Director/Board Member | 58 | 20-08-11 | |
| Director/Board Member | 62 | 20-07-31 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 455,750,104 | 240,790,322 ( 52.83 %) | 0 | 52.83 % |
Company contact information
Lupin Ltd.
Kalpataru Inspire Off Western Expressway Highway
400055, Mumbai
+91 22 6640 2323
http://www.lupin.com
Group companies
| Name | Category and Sector |
|---|---|
Nanomi BV
 Nanomi BV Chemicals: SpecialtyProcess Industries Part of Lupin Ltd., Nanomi BV is a Dutch company that manufactures drugs. The private company is based in Oldenzaal, the Netherlands. Okke Franssen has been the CEO of the company since 2016. Nanomi was acquired by Lupin Ltd. on February 03, 2014. |
Chemicals: Specialty
|
Lupin Atlantis Holdings SA
 Lupin Atlantis Holdings SA Pharmaceuticals: MajorHealth Technology Part of Lupin Ltd., Lupin Atlantis Holdings SA is a holding Swiss company that manufactures and distributes pharmaceutical products. The private company is based in Zug, Switzerland. |
Pharmaceuticals: Major
|
Sector
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,607
INR
Average target price
1,514
INR
Spread / Average Target
-5.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 659B | |
| +25.91% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.15% | 215B | |
| +8.04% | 210B | |
| -6.26% | 200B | |
| -8.79% | 149B |
- Stock Market
- Equities
- LUPIN Stock
- LUPIN Stock
- Company Lupin Limited
